Two other fAABs that were also present in 29 (90%) of the 31 investigated post-COVID-19 patients were directed against the angiotensin II AT1 receptor (fAT1-AAB) and the angiotensin 1-7 MAS receptor (MAS-AAB). The gene discussed is MAS1; the disease is COVID-19.